Published online before print October 11, 2007, doi: 10.1161/ATVBAHA.107.152462
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 American Heart Association, Inc.
Thrombosis |
Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production
From the Department of Medicine (R.L.C.H., W.S.C., M.H.Y., A.X., A.W.K.T., H.F.T., C.H.Y.F., K.S.L.L.) and the Research Centre of Heart, Brain, Hormone, and Healthy Aging (A.X., H.F.T., S.T., K.S.L.L.), LKS Faculty of Medicine, The University of Hong Kong, China; the Clinical Biochemistry Unit (S.T.), Queen Mary Hospital, Hong Kong, China; and the Division of Diabetes, Endocrinology, and Metabolism (L.C.), Departments of Medicine and Molecular & Cellular Biology, Baylor College of Medicine, Houston, Tex.
Correspondence to Prof Karen S.L. Lam, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. E-mail ksllam{at}hkucc.hku.hk
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— The purpose of this study was to examine the effects of PPAR-
agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. Methods and Results— Our clinical study (n=64) showed that after 24-week add-on therapy, the rosiglitazone group had a greater mean reduction in plasma PAI-1 levels (25%, versus 12% in sulfonylurea group, P=0.002). Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone (20 mg/kg/d) reduced adipose tissue PAI-1 mRNA expression and its plasma levels in wild-type C57 mice with diet-induced obesity (P<0.001), but this suppressive effect was attenuated in adiponectin knockout mice. Adenovirus-mediated overexpression of adiponectin led to a significant suppression of adipose tissue PAI-1 expression and its circulating concentrations in db/db diabetic mice. Our in vitro study demonstrated that recombinant adiponectin directly inhibited PAI-1 production in 3T3-L1 adipocytes.
Conclusions— The antithrombotic effect of rosiglitazone is mediated, at least in part, through the suppressive effect of adiponectin on PAI-1 production.
We demonstrated that rosiglitazone-mediated elevation of plasma adiponectin level is independently associated with the reduction in PAI-1 concentrations in diabetic patients. The suppressive effect of rosiglitazone on PAI-1 production was attenuated in adiponectin-deficent mice, whereas over-expression of adiponectin decreased PAI-1 production. Recombinant adiponectin inhibited PAI-1 expression in 3T3-L1 adipocyte.
Key Words: obesity • hyperglycemia • adipokines • thrombotic dieases
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Plasminogen activator inhibitor (PAI)-1, a member of the serine protease inhibitor family, regulates thrombus formation through the inhibition of tissue plasminogen activator, an anticlotting factor, and plays a key role in the pathogenesis of cardiovascular events. In apolipoprotein E–deficient mice, an accelerated atherosclerosis animal model, PAI-1 deficiency protects against atherosclerosis progression after photochemical injury to carotid atherosclerotic plaques,1 and reduces neointima formation after oxidative, and copper induced arterial injuries.2,3 Likewise, increased PAI-1 expression, mediated by an adenoviral vector, has been shown to promote neointima growth in balloon-injured rat carotid arteries.4 In clinical studies, elevated plasma PAI-1 levels are found in subjects with atherosclerotic diseases5,6 and have been shown to predict the development of cardiovascular events.7,8 In middle-aged men, a high baseline plasma PAI-1 level increases the prediction of coronary heart disease and ischemic stroke, in addition to conventional risk factors.8
Subjects with obesity, impaired glucose tolerance, and type 2 diabetes, conditions known to be associated with insulin resistance, have elevated PAI-1 levels,9,10 which correlate with peripheral insulin resistance, assessed by hyperinsulinemic euglycemic clamp study.11 In addition, pharmacological therapies with insulin sensitizers such as biguanide and thiazolidinediones have been shown to reduce circulating PAI-1 levels in subjects with type 2 diabetes.12,13 In cultured human preadipocytes, a direct attenuation of PAI-1 mRNA and protein expression by thiozolidinediones, possibly mediated through PPAR- activation, has been demonstrated.14 It should be noted that within the adipose tissue, preadipocytes, dominating the stromal cell fraction, is an important source of PAI-1 production,15 especially in subjects with visceral obesity.
The mechanism whereby PPAR- agonists reduce PAI-1 expression in adipose tissue is unclear. One possibility is that this may be mediated through other adipokines, such as adiponectin and tumor necrosis factor (TNF)-
, the dysregulation of which in type 2 diabetes and obesity is also ameliorated by PPAR- agonists.16,17 An inverse relationship between circulating adiponectin and PAI-1 levels has been previously reported in patients with coronary artery disease.18 In contrast to PAI-1, serum adiponectin levels are reduced in type 2 diabetes, obesity, and coronary artery disease, and high levels are protective against cardiovascular diseases in humans and animals.19 We hypothesize that adiponectin, an insulin-sensitizing and antiatherogenic adipokine which exhibits a 2-fold increase on thiazolidinedione therapy,16 mediates the suppressive effect of PPAR- agonists on circulating PAI-1 levels. Here we report our findings from clinical, animal, and in vitro studies which have provided support for this hypothesis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Clinical Study
Subjects
The effects of rosiglitazone versus sulfonylurea on circulating PAI-1 and adiponectin levels, were investigated in a randomized, open-label, parallel group study. The study involved 64 Chinese subjects with type 2 diabetes, treated with diet alone, metformin, or sulfonylurea <half-maximum dose for at least 6 months, with suboptimal glycemic control, as defined by HbA1c
7.5%. Patients were randomly assigned to receive add-on therapy with either rosiglitazone 4 mg or sulfonylurea (glibenclamide 5 mg or gliclazide 80 mg) daily for 4 weeks, while keeping the doses of their usual antidiabetic agents constant. The doses of the add-on therapy were doubled after 4 weeks in subjects with fasting blood glucose level >8.0 mmol/L and without symptomatic or asymptomatic hypoglycemia, defined as blood glucose level <3.0 mmol/L. The final doses of all antidiabetic agents were then kept constant for another 20 weeks. The study protocol was approved by the local Institutional Review Board, and written informed consent was obtained from all subjects.
Biochemical Measurements
Circulating PAI-1 level was measured in fasting blood samples taken at 9 to 10 AM, by using an in-house human PAI-1 ELISA kit, as described in the supplemental materials (available online at http://atvb.ahajournals.org). Serum adiponectin level was also determined with an in-house ELISA assay.20 Plasma high-sensitivity C-reactive protein (hs-CRP) was measured with a particle-enhanced immunoturbidimetric assay (Roche).20 Serum malondialdehyde (MDA) and total plasma 8-isoprostane was measured using OXI-TEK TBARS assay kit (Alexis Biochemicals) and a specific enzyme immunoassay kit (Cayman Chemical), respectively. Serum insulin measurement and other biochemical assays were performed as previously described.21
Animal Studies
Mice
C57BL/6N mice and C57BL/KsJ db/db diabetic mice were purchased from the Jackson ImmunoResearch Laboratories, Inc., West Grove, PA. The adiponectin-knockout (adiponectin-KO) mice with C57BL/6J background21 were generated at the laboratory of Lawrence Chan (Baylor College, University of Texas, Houston). C57 BL/6N (wild-type) mice and adiponectin-KO mice with diet-induced obesity were generated by allowing free access of a high-fat diet (45 kcal% from fat, D12451, Research Diet), from the age of 4 weeks.
Study Protocol
Mice used in this experiment were 10 to 12 weeks of age, housed in a room at controlled temperature [23±1 C] with a 12 hour light-dark cycle, and had free access to water and standard mouse diet (db/db and control C57 BL/6N) or high-fat diet. Rosiglitazone (20 mg/kg) (GSK) was daily administrated to wild-type and adiponectin-KO mice with diet-induced obesity by intragastric gavage for 2 weeks. Recombinant adenoviruses expressing murine adiponectin or luciferase (as a control) were produced as we previously described,22 and 108 pfu of the recombinant adenovirus were introduced into db/db diabetic mice through tail-vein injection. Mice were fasted for 6 hours (steady-state) and blood glucose levels were measured using Accu-Check Advantage II Glucometer (Roche) before euthanized at day 14 after adenovirus injection. Circulating levels of mouse PAI-1 and adiponectin were measured using the mouse adipokine assay kit from Linco Research23 and an in-house adiponectin ELISA assay, respectively.24 The mRNA abundance of PAI-1 in adipose tissue was quantified using real-time polymerase chain reaction (PCR) as we described elsewhere.23 All of the experiments were conducted in accordance with our institutional guidelines for the humane treatment of laboratory animals.
Statistical Analysis
All continuous variables are expressed as mean±SEM or median and interquartile range, if the data were not normally distributed. Statistical analyses were performed using the SPSS 13.0 software package (SPSS). Comparison of variables between 2 groups was performed using independent sample t test or paired t test as appropriate. Skewed data were logarithmically transformed before analysis. The log-change ratio was obtained by taking the log of the ratio of the postmeasurement to the premeasurement. Stepwise multiple linear regression analyses were used to examine the association of PAI-1 reduction with the changes in other parameters which showed a significant change in the rosiglitazone group, but not in the sulfonylurea group, after Bonferroni correction for multiple testing. A 2-sided value of P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Changes in Serum Adiponectin and Fasting Blood Glucose Were Independently Associated With the PAI-1 Reduction in Rosiglitazone-Treated Patients
The study subjects received add-on therapy with either rosiglitazone (21 M+11 F; aged 55.4±9.8 years) or sulfonylurea (15 M+17 F; aged 57.1±10.1 years). Baseline clinical characteristics, metabolic profiles and concomitant medications were similar between the 2 groups except that current smoking was more prevalent in the rosiglitazone group (22 versus 9%, P<0.05). The difference in baseline PAI-1 levels between the 2 groups was not statistically significant (P=0.087). The changes in cardiometabolic parameters, versus baseline values, after 24-week of add-on therapy are summarized in Table 1: both rosiglitazone and sulfonylurea resulted in significant reductions in HbA1c, fasting plasma glucose, and MDA. Both treatment groups also had a significant reduction in PAI-1 (–25.2%, P<0.001 and –11.9%, P=0.001, respectively), with a greater reduction being seen in the rosiglitazone group (P=0.002 versus sulfonylurea group). Plasma adiponectin showed a marked rise in the rosiglitazone group (P<0.001), whereas only a slight, albeit statistically significant increase (P=0.036) was seen in the sulfonylurea group. Rosiglitazone, but not sulfonylurea, significantly reduced HOMA-IR and free fatty acid (FFA). Neither group showed a significant change in fasting insulin. A significant change in BMI was seen only in the rosiglitazone group.
|
After Bonferroni’s correction for multiple comparisons, the parameters with significant change in the rosiglitazone group, but not in the sulfonylurea group, included fasting glucose (and hence HOMA-IR), BMI, adiponectin, and FFA. On stepwise multiple linear regression analysis, only the changes in fasting glucose and adiponectin were significantly and independently associated with the reduction in PAI-1 in the rosiglitazone group. These 2 parameters accounted for 43.8% of the total variation in PAI-1, with 15.6% being explained by the change in adiponectin level (Table 2).
|
The Suppressive Effects of Rosiglitazone on PAI-1 Expression Was Attenuated in Adiponectin-KO Mice
To investigate whether rosiglitazone reduced circulating PAI-1 levels through its effect on adiponectin expression, both adiponectin-KO mice and the wild-type littermates (controls) were fed with a high-fat diet and treated with daily high dose rosiglitazone for 2 weeks. In wild type mice with diet-induced-obesity (DIO), rosiglitazone treatment significantly increased serum adiponectin concentrations (vehicle: 12.4±3.7 µg/mL; Rosiglitazone: 21.6±5.9 µg/mL, P=0.016), and also markedly reduced the PAI-1 expression level in their adipose tissue (Figure 1a). On the other hand, there was only a small but statistically significant reduction of PAI-1 expression in adiponectin-KO mice with DIO. After rosiglitazone treatment in the mice with DIO, plasma PAI-1 concentrations were also significantly decreased in control mice (Vehicle: 47.7.±8.3 ng/mL, Rosiglitazone: 24.1±5.2 ng/mL, P=0.013, n=10), whereas the reduction was not statistically significant in the adiponectin-KO mice (Vehicle: 54.5±7.9; Rosiglitazone: 42.3±6.7; P=0.074; n=10; Figure 1b). Furthermore, the magnitude of rosiglitazone-mediated decrease in PAI-1 concentration in control mice was significantly greater than that in adiponectin-KO mice (control with DIO: 49.7±6.6%; KO mice with DIO: 22.6±3.5%,; P=0.018). Rosiglitazone treatment reduced plasma glucose levels at steady states (6-hour fasting) to a similar extent in KO and control mice (Figure 1c).
|
PAI-1 Expression Was Increased in db/db Diabetic Mice and Suppressed by Adenovirus-Mediated Overexpression of Adiponectin
Serum adiponectin levels at baseline were 12.7±2.6 µg/mL. After injection of adiponectin-expressing adenoviruses, serum adiponectin started to rise on day 2 (18.9±3.2 µg/mL), peaked on day 7 (40.1±6.7 µg/mL), and then gradually decreased to the basal level by day 21. Injection of luciferase-expressing adenovirus did not affect serum adiponectin levels in db/db mice. PAI-1 expression level in db/db diabetic mice was significantly higher than that in the lean controls. In both db/db diabetic mice and lean controls, overexpression of adiponectin alone significantly reduced PAI-1 expression in adipose tissues, and concomitantly decreased circulating PAI-1 concentrations (Figure 2; wild-type/luciferase: 24.1±1.08 ng/mL, wild-type/adiponectin: 16.96±0.44 ng/mL, P=0.042; db/db/luciferase: 62.5±3.12 ng/mL; db/db/adiponectin:34.8±2.39 ng/mL, P=0.001).
|
Recombinant Adiponectin Directly Inhibited PAI-1 in 3T3-L1 Adipocytes
The direct effect of adiponectin on PAI-1 expression in 3T3-L1 adipocytes was investigated. Chronic treatment of mature adipocytes with recombinant full-length adiponectin caused a marked reduction of PAI-1 mRNA expression in a dose-dependent manner (Figure 3). PAI-1 concentrations in the conditioned medium decreased by 
33% and 62% after treatment with adiponectin at the concentrations of 5 µg/mL and 10 µg/mL, respectively.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Increased PAI-1 expression has been suggested to contribute to the enhanced atherothrombotic risk in type 2 diabetes.25,26 In this study, we had confirmed that treatment with rosiglitazone, a thiazolidinedione antidiabetic drug, could reduce circulating levels of PAI-1 in diabetic patients.27 We further showed that changes in glycemia and serum adiponectin levels were independently associated with changes in PAI-1 levels in rosiglitazone-treated patients. The greater reduction in fasting glucose induced by rosiglitazone (mean dose 6 mg/d), compared with that achieved by sulfonylurea add-on therapy, suggested that a greater improvement in glycemia could have contributed to a greater reduction in PAI-1 levels in the rosiglitazone group. Our data also suggested that the almost 2-fold increase in circulating adiponectin levels in the rosiglitazone-treated patients could have contributed independently to the reduction in PAI-1 levels in these patients.
Our findings were at variance with another study which showed that pioglitazone did not reduce significantly plasma PAI-1 levels, despite elevations in adiponectin,28 although a trend of reduction was apparent. It should be noted that the previous study involved half our sample size and treatment duration, and a relatively lower treatment dose, and the authors conceded that the baseline PAI-1 levels of their patients may not be high enough to accurately assess the lowering effect of pioglitazone.
Our clinical study suggested that adiponectin might be involved in the regulation of PAI-1 expression. Previous studies demonstrated that PAI-1 expression could be upregulated by hyperglycemia,29 FFA, triglycerides, insulin, transforming growth factor (TGF)-β, angiotensin II, CRP, and TNF-.30 However, the regulation of PAI-1 expression by adiponectin had not been previously reported. We therefore investigated this possibility in 2 sets of animal experiments.
Previous studies reported that a high dose of pioglitazone could reduce insulin resistance even in ob/ob mice with adiponectin deficiency, possibly through PPAR- induced reductions in TNF- and resistin expression, and FFA levels.31 In this study, high-dose rosiglitazone could also reduce hyperglycemia in mice with diet-induced obesity, independent of the presence of adiponectin. However, whereas the glucose-lowering effect of high-dose rosiglitazone in the obese mice with adiponectin deficiency was similar to that in wild-type obese mice, the rosiglitazone-induced reduction in PAI-1 expression in epididymal fat was much attenuated in adiponectin-deficient mice. These data suggest that the effect of rosiglitazone on adipose tissue PAI-1 expression is, to a large extent, adiponectin-dependent. Other effects of high-dose rosiglitazone, which may be adiponectin-independent, such as an inhibition of angiotensin II action,32 or the reduction of insulin resistance and hence hyperinsulinaemia and hyperglycemia,33 could have contributed to the small reduction in PAI-1 expression in adiponectin-deficient mice.
To further investigate the role of adiponectin in regulating PAI-1 expression, suggested by our clinical findings and supported by the loss-of-function animal study, we treated db/db diabetic mice and control lean mice with recombinant adenovirus expressing adiponectin or luciferase (as control). The obese diabetic mice had much higher PAI-1 gene expression in their adipose tissue, compared with lean controls, analogous to increased PAI-levels in humans with obesity and insulin resistance.34 We found that overexpression of adiponectin in vivo could indeed reduce PAI-1 gene expression in epididymal fat, a visceral depot, in both diabetic and lean mice. Our in vitro study showed that adiponectin can directly suppress PAI-1 production in 3T3-L1 adipocytes. In addition to its direct effects on adipocytes, adiponectin might also suppress PAI-1 production through indirect mechanisms. For example, adiponectin has insulin-sensitizing and antiinflammatory properties.19 It also increases fatty acid oxidation and reduces the synthesis of fatty acids and triglyceride.33 Furthermore, adiponectin may reduce PAI-1 production through suppressing the production of other adipokines, such as TNF-, which stimulates PAI-1 gene expression in human adipocytes.34
PPAR is predominantly expressed in adipose tissue, and adiponectin is almost exclusively secreted from adipocytes. Thiazolidinediones stimulate adiponectin production via enhancing adiponectin secretion from adipocytes.35 It is conceivable that the reported direct effect of PPAR agonists on suppressing PAI-1 expression in human adipose tissue14 is mediated partly via adiponectin. Although our data clearly demonstrated the important role of adiponectin in mediating the suppressive effects of rosiglitazone on PAI-1, rosiglitazone can still reduce PAI-1 expression in adiponectin-deficient mice (albeit to a much less extent), suggesting the involvement of other adiponectin-independent mechanisms. Indeed, recent studies suggest that macrophage-adipocyte interaction plays a key role in initiating the inflammatory response associated with obesity.36 The PPAR agonists can directly act on macrophages to decrease the production of proinflammatory cytokines, including IL1β, TNF, and IL6,37 which in turn will alleviate their stimulatory effect on adipocyte PAI-1 production. Consistent with our findings, a recent study suggests that pioglitazone ameliorates insulin resistance and diabetes in both adiponectin-dependent and -independent pathways.31
In conclusion, our studies have provided, for the first time, evidence to support a beneficial effect of adiponectin on PAI-1 expression. Thus, in addition to its pleiotropic metabolic, antiatherogenic, antiinflammatory, and antioxidant actions,19 this antithrombotic property of adiponectin may contribute to the potential vasoprotective effects of drugs which can increase adiponectin production, such as the thiazolidinediones.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by grants from the Hong Kong Research Grant Council (7404/04 M and 7637/05M) to K.S.L.L., Innovation and Technology Commission to A.X. (GHP/27/05), and HL-51586 and DK-68037 to L.C.
Disclosures
None.
|
Footnotes |
|---|
R.L.C.H. and W.S.C. contributed equally to this study.
Original received May 25, 2007; final version accepted September 28, 2007.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000; 96: 4212–4215.
2. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation. 2001; 103: 3105–3110.
3. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol. 2001; 158: 107–117.
4. DeYoung MB, Tom C, Dichek DA. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation. 2001; 104: 1972–1971.
5. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction–the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost. 1998; 80: 749–756.[Medline] [Order article via Infotrieve]
6. Zunker P, Schick A, Padro T, Kienast J, Phillips A, Ringelstein EB. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology. Neurol Res. 1999; 21: 727–732.[Medline] [Order article via Infotrieve]
7. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998; 98: 2241–2247.
8. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005; 112: 3080–3087.
9. Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism. 1998; 47: 1372–1375.[CrossRef][Medline] [Order article via Infotrieve]
10. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2002; 25: 1340–1345.
11. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 1993; 42: 945–949.[CrossRef][Medline] [Order article via Infotrieve]
12. Grant P. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003; 29 (4 Pt 2): 6S44–52.[Medline] [Order article via Infotrieve]
13. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000; 49: 633–639.[Abstract]
14. Zirlik A, Leugers A, Lohrmann J, Ernst S, Sobel BE, Bode C, Nordt TK. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemo st. 2004; 91: 674–682.
15. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol. 2002; 22: 173–178.
16. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002; 51: 2968–2974.
17. Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza EC, Adachi Y. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab. 2000; 2: 189–191.[CrossRef][Medline] [Order article via Infotrieve]
18. Maruyoshi H, Kojima S, Funahashi T, Miyamoto S, Hokamaki J, Soejima H, Sakamoto T, Kawano H, Yoshimura M, Kitagawa A, Matsuzawa Y, Ogawa H Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost. 2004 91: 1026–1030.[Medline] [Order article via Infotrieve]
19. Lam KS, Xu A. Adiponectin: protection of the endothelium. Curr Diab Rep. 2005; 5: 254–259.[Medline] [Order article via Infotrieve]
20. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a Predictor for the Development of Hypertension. A 5-Year Prospective Study. Hypertension. 2007; 49: 1455–1461.
21. Ma K, Cabrero A, Saha PK, Kojima H, Li L, Chang BH, Paul A, Chan L. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002; 277: 34658–34661.
22. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, Hoo RC, Mak WW, Cooper GJ, Xu A. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem. 2006; 281: 16391–16400.
23. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun. 2006; 341: 549–556.[CrossRef][Medline] [Order article via Infotrieve]
24. Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology. 2004; 145: 487–494.
25. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, Vitacolonna E, Capani F, Consoli A. Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects. Arterioscler Thromb Vasc Biol. 2001; 21: 1378–1382.
26. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998; 97: 2213–2121.
27. Derosa G, Cicero AF, Gadd A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo PD, Ciccarelli L, Fogari R. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005; 69: 5–13.[CrossRef][Medline] [Order article via Infotrieve]
28. Aso Y, Yamamoto R, Suetsugu M, Matsumoto S, Wakabayashi S, Matsutomo R, Takebayashi K, Inukai T. Comparison of the effects of pioglitazone and voglibose on circulating total and high molecular weight adiponetin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet. Med. In press.
29. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L, Lorenzi M. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes. 1992; 41: 1009–1015.[Abstract]
30. Darvall KAL, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007; 33: 223–233.[CrossRef][Medline] [Order article via Infotrieve]
31. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006; 281: 8748–8755.
32. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab. 1987; 13: 331–336.[Medline] [Order article via Infotrieve]
33. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112: 91–100.[CrossRef][Medline] [Order article via Infotrieve]
34. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol. 2000; 20: 1682–1687.
35. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab. 2006; 291: E1100–E1105.
36. Bouloumie A, Curat CA, Sengenes C, Lolmede K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care. 2005; 8: 347–354.[Medline] [Order article via Infotrieve]
37. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes. 2000 49: 346–355.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  R. B. Goldberg Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3171 - 3182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C.Y. Yeung, A. Xu, A. W.K. Tso, W.S. Chow, N. M.S. Wat, C. H.Y. Fong, S. Tam, P. C. Sham, and K. S.L. Lam Circulating Levels of Adipocyte and Epidermal Fatty Acid-Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic Patients Diabetes Care, January 1, 2009; 32(1): 132 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chandrasekar, D. N. Patel, S. Mummidi, J.-w. Kim, R. A. Clark, and A. J. Valente Interleukin-18 Suppresses Adiponectin Expression in 3T3-L1 Adipocytes via a Novel Signal Transduction Pathway Involving ERK1/2-dependent NFATc4 Phosphorylation J. Biol. Chem., February 15, 2008; 283(7): 4200 - 4209. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||